Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Elementis gains as investors cheer H1 operating profit growth

(Sharecast News) - Speciality chemicals firm Elementis traded higher early on Thursday as it unveiled a new strategic framework aimed at accelerating growth and returns following a "strong financial performance" in H1. Elementis said revenues had dipped 1% on a constant currency basis to $308m in the six months ended 30 June, reflecting softer demand in coatings. However, adjusted operating profits climbed 7% to $65m, with margins improving to 21% from 20% a year earlier.

Personal care led the charge, delivering record margins of 34% on the back of product innovation and cost savings, including the closure of its Middletown plant, while coatings revenue fell 4% amid weaker volumes across all regions.

The FTSE 250-listed group, which completed the sale of its Talc business in May, booked a $100m discontinued loss but significantly reduced net debt by 36% to $125m. A $50m buyback programme, funded by the sale proceeds, was said to be progressing as planned.

Elementis also declared an interim dividend of 1.3 cents per share, up from 1.1 cents in FY24, and kept its FY profit expectations unchanged.

CEO Luc van Ravenstein said: "I am pleased to report that the business has continued to build positive operational momentum, delivering a strong first-half performance. Both profits and margins from continuing operations are up on the prior year. This performance underscores the resilience and quality of our business during a period of soft market demand."

As of 1035 BST, Elementis shares were up 6.59% at 171.40p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.